Benjamin L Schlechter
Overview
Explore the profile of Benjamin L Schlechter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huffman B, Rahma O, Tyan K, Li Y, Giobbie-Hurder A, Schlechter B, et al.
Cancer Immunol Res
. 2024 Sep;
13(1):9-22.
PMID: 39348472
Ovarian cancers and microsatellite stable (MSS) colorectal cancers are insensitive to anti-programmed cell death 1 (PD-1) immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggest a relationship between immunotherapy...
2.
Oberstein P, Dias Costa A, Kawaler E, Cardot-Ruffino V, Rahma O, Beri N, et al.
Cancer Immunol Res
. 2024 Jul;
12(9):1221-1235.
PMID: 38990554
Innate inflammation promotes tumor development, although the role of innate inflammatory cytokines in established human tumors is unclear. Herein, we report clinical and translational results from a phase Ib trial...
3.
Bullock A, Schlechter B, Fakih M, Tsimberidou A, Grossman J, Gordon M, et al.
Nat Med
. 2024 Jun;
30(9):2558-2567.
PMID: 38871975
Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody...
4.
Schlechter B, Stebbing J
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38719543
The CCR/L5 axis is known for its role in immune regulation in a variety of settings and has been shown to have dichotomous functions in cancer, influencing both tumor progression...
5.
Ko A, Coveler A, Schlechter B, Bekaii-Saab T, Wolpin B, Clark J, et al.
Invest New Drugs
. 2024 Mar;
42(2):221-228.
PMID: 38441850
AbGn-107 is an antibody-drug conjugate directed against AG-7 antigen, a Lewis A-like glycol-epitope expressed in a variety of gastrointestinal (GI) malignancies. Based on promising antitumor activity of AbGn-107 in both...
6.
Singh H, Sahgal P, Kapner K, Corsello S, Gupta H, Gujrathi R, et al.
Clin Cancer Res
. 2024 Feb;
30(8):1669-1684.
PMID: 38345769
Purpose: ERBB2-amplified colorectal cancer is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. Experimental Design: Dana-Farber and Foundation Medicine Inc. Colorectal cancer...
7.
Stebbing J, Schlechter B
J Clin Oncol
. 2023 Dec;
42(4):369-372.
PMID: 38060992
No abstract available.
8.
Huffman B, Feng H, Parmar K, Wang J, Kapner K, Kochupurakkal B, et al.
Clin Cancer Res
. 2023 Oct;
29(24):5047-5056.
PMID: 37819936
Purpose: Combining gemcitabine with CHK1 inhibition has shown promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC). Here, we report the findings from a phase I expansion cohort study (NCT02632448)...
9.
Singh H, Keller R, Kapner K, Dilly J, Raghavan S, Yuan C, et al.
Clin Cancer Res
. 2023 Jul;
29(22):4627-4643.
PMID: 37463056
Purpose: Approximately 8% to 10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is...
10.
Singh H, Klempner S, Melnitchouk N, Chander D, Negrea O, Patel A, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2200572.
PMID: 37343200
Purpose: GI cancers commonly spread to the peritoneal cavity, particularly from primary adenocarcinomas of the stomach and appendix. Peritoneal metastases are difficult to visualize on cross-sectional imaging and cause substantial...